#United States #Robbins Geller #San Diego #Class Action #Lantheus Holdings

Robbins Geller Takes Action Against Lantheus Holdings

In a significant move for investors, Robbins Geller Rudman & Dowd LLP has filed a class action lawsuit against Lantheus Holdings, Inc. This lawsuit, labeled Indiana Public Retirement System v. Lantheus Holdings, Inc., seeks to represent buyers of the company's common stock from November 6, 2024, to August 6, 2025, a period marked by contentious trading and disappointing earnings reports.

The Allegations

The class action accuses Lantheus and its top executives of breaching the Securities Exchange Act of 1934. The firm notably presents itself as an innovator in the medical technology sector, specifically in radiopharmaceuticals with its leading product, Pylarify. However, the lawsuit claims that Lantheus’s portrayal of its financial health and business diversification was misleading.

Throughout the class period, Lantheus purportedly depicted itself as a multi-faceted company with a robust growth trajectory and reliable revenue sources. Nevertheless, the lawsuit contends that the company relied almost entirely on Pylarify, which generated the majority of its income. Documents suggest that the management was acutely aware of the unreliable nature of its financial forecasts and underestimated the pricing challenges stemming from new reimbursement policies introduced by the Centers for Medicare & Medicaid Services.

The Decline in Stock Value

As investigations into Lantheus’s financial practices were conducted, the company faced significant stock value declines. On May 7, 2025, Lantheus reported its first quarter results, revealing that sales for Pylarify had fallen short of expectations, leading to a 23% drop in share price. Further complicating matters, a subsequent disclosure on August 6, 2025, revealed an 8% year-over-year decline in Pylarify revenue and ongoing contract renegotiations, resulting in a dramatic almost 29% plummet in share price. This alarming trend underscores the concerns that investors have regarding the transparency of Lantheus’s operations.

Lead Plaintiff Opportunity

Investors who incurred significant losses during the class period are encouraged to act as lead plaintiffs by submitting their information through the designated channels outlined by Robbins Geller. Their involvement could potentially guide the lawsuit and shape its outcomes, giving a voice to a community of investors collectively seeking recovery of their losses. The window for filing lead plaintiff motions closes on November 10, 2025, and interested parties are advised to respond promptly.

About Robbins Geller Rudman & Dowd LLP

Known for its prowess in securities fraud litigation, Robbins Geller Rudman & Dowd LLP has solidified its reputation as one of the leading firms dedicated to protecting investor rights. The firm has consistently ranked at the top for recovering substantial financial compensation for its clients. Their track record speaks volumes—over $2.5 billion recovered in 2024 alone, earning them recognition as a formidable player in the investor legal arena.

As this class action unfolds, it reinforces the critical role that investor advocacy firms play in maintaining corporate accountability and safeguarding shareholder interests in an often unpredictable financial landscape. Investors are encouraged to stay updated regarding the lawsuit’s developments and potential resolutions as the case progresses through the legal system.

For more detailed information regarding submitting a lead plaintiff motion or insights into this case, interested parties can contact Robbins Geller representatives directly.